Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy

Developmental Medicine and Child Neurology

Volumn 53, Issue 6, 2011, Pages 535-542

  Mayhew, Anna ^a   Cano, Stefan ^b   Scott, Elaine ^c   Eagle, Michelle ^a   Bushby, Kate ^a   Muntoni, Francesco ^d   On Behalf of the NorthStar Clinical Network for Paediatric Neuromuscular Disease, ^e  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c Muscular Dystrophy Campaign   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AMBULATORY MONITORING; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; LEG; MALE; NORTH STAR AMBULATORY ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMETRY; RASCH ANALYSIS; RATING SCALE; RELIABILITY; SCHOOL CHILD;

EID: 79956006620     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2011.03939.x     Document Type: Article

References (27)

1. Drousiotou A, Ioannou P, Georgiou T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998; 2: 55-60.
2. Bradley D, Parsons E. Newborn screening for Duchenne muscular dystrophy. Semin Neonatol 1998; 3: 27-34.
3. Emery AE. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991; 1: 19-29.
4. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
5. Manzur AY, Kuntzer T, Pike M, Swan AV. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; 1: CD003725.
6. Scott E, Eagle M, Main M, Sheehan J. The North Star Ambulatory Assessment. Poster presented at the Annual Meeting of the British Paediatric Neurology Association, 2006. Dev Med Child Neurol 2006; 48 (Suppl. 104): 27.
7. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression in Duchenne muscular dystrophy: a single blind, placebo-controlled dose escalation study using morpholino antisense oligomer AVI-4658. Lancet Neurol 2009; 8: 918-28.
8. Shrewsbury SB, Cirak S, Guglieri M, Bushby K, Muntoni F. Current progress and preliminary results with the systematic administration trial of AVI-4658, a novel phosophorodiamidate morpholino oligomer (PMO) skipping dystrohin exon 51 in Duchenne muscular dystrophy (DMD) World Muscle Society Meeting, Kumamoto, Japan 12-16th October, 2010. Neuromuscul Disord 2010; 20: 639-40.
9. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007; 6: 1094-105.
10. Cano SJ, Hobart JC. Watch out, watch out, the FDA are about. Dev Med Child Neurol 2008; 50: 408-9.
11. Novick MR. The axioms and principal results of classical test theory. J Math Psychol 1966; 3: 1-18.
12. Hobart JC, Cano SJ. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Monogr UK Health Technol Assess Prog 2009; 13: 1-200.
13. Wright BD, Linacre JM. Observations are always ordinal: measurements, however must be interval. Arch Phys Med Rehabil 1989; 70: 857-60.
14. Wright BD, Stone MH. Best Test Design: Rasch Measurement. Chicago, IL: MESA, 1979.
15. Mazzone ES, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009; 19: 458-61.
16. Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests. Copenhagen: Danish Institute for Education Research, 1960.
17. Spearman C. The proof and measurement of association between two things. Am J Psychol 1904; 15: 72-101.
18. Wright BD, Masters G. Rating Scale Analysis: Rasch Measurement. Chicago, IL: MESA, 1982.
19. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006; 129: 224-34.
20. Hagquist C, Andrich D. Is the Sense of Coherence instrument applicable on adolescents? A latent trait analysis using Rasch modelling. Pers Individ Diff 2004; 36: 955-68.
21. Andrich D. Distinctions between assumptions and requirements in measurement in the social sciences. In: Keats JA, Taft R, Heath RA, Lovibond SH, editors. Proceedings of the XXIVth International Congress of Psychology. North Holland: Elsevier Science Publications BV, 1989: 7-16.
22. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334.
23. RUMM Laboratory. RUMM2020, Version 4.0 for Windows (Upgrade 4600.0109). Perth, Western Australia: RUMM Laboratory, 19972007.
24. Scott OM, Hyde SA, Goddard C, Dubowitz V. Prevention of deformity in Duchenne muscular dystrophy. A prospective study of passive stretching and splintage. Physiotherapy 1981; 67: 177-80.
25. Hyde SA, Fløytrup I, Glent S, et al. A randomized comparative study of two methods for controlling tendo achilles contracture in Duchenne muscular dystrophy. Neuromuscul Disord 2000; 10: 257-63.
26. Steffensen B, Hyde S, Lyager S, et al. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 2001; 6: 119-34.
27. Steffensen BF, Lyager S, Werge B, Rahbek J, Mattson E. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol 2002; 44: 623-32.